ASTRAZENECA PHARMA INDIA
BSE ticker code |
506820 |
NSE ticker code |
ASTRAZEN |
Major activity |
Pharmaceuticals |
Managing Director |
Narayan K. Seshadri |
Equity capital |
Rs. 5.00 crore; FV Re. 02 |
52 week high/low |
Rs. 3375 / Rs. 2437 |
CMP |
Rs. 3302.00 |
Market Capitalisation |
Rs. 8255.00 crore |
Recommendation |
Accumulate at declines |
Focus on crucial health molecules
Bengaluru-headquartered AstraZeneca Pharma is
a subsidiary of AstraZeneca Ple UK, a $37,417 billion-insales MNC pharmaceutical giant
having a portfolio of products for major diseases in areas including oncology,
cardiovascular, gastro-intestinal, infection, neuroscience, respiratory
and inflammation. It has been involved in developing the
Oxford-AstraZeneca Covid-19 vaccine. A BSE-listed company
which has a workforce of 1,400 across
the country, it is committed to providing life-changing medicines to patients
through innovative science and global
excellence in development and commercialization. The company has an
innovative portfolio in crucial areas of
healthcare, including cardiovascular,
renal and metabolic diseases, oncology and respiratory.
The company’s Bengaluru manufacturing facility has been rated the finest in Southeast
Asia with a state-of-theart production facility that meets stringent international
standards, including WHO-Good Manufacturing Practices (GMP)
norms. Some of the company’s key brands include Forxiga,
Brilinta, Imfinzi, Lynparza, Xigaduo Qutern and Zoladex.
The company has been going from strength to strength
on the sales front, with the turnover steadily expanding from
Rs 594 crore in fiscal 2011 to Rs 806 crore in fiscal 2022.
However, its performance on the profitability front is disappointing, with its
operating profit which was Rs 104 crore in
fiscal 2011 turning negative in fiscal 2013 with a loss of Rs
68 crore and remaining in the red for the next year. However, subsequently, the company
has started earning a profit
which gradually edged up to Rs 135 crore in fiscal 2021
before declining to Rs 86 crore in fiscal 2022. Its prospects
going ahead are highly promising.
Consider:
-
Going ahead, the company will continue to
prioritise investments in its focus areas in line with its global
growth platforms. Accordingly, new products remain a key
priority and it is committed to maintaining alignment with
the global pipeline, subject to conduct of clinical trials, regulatory
approvals and reasonable commercial viability. A
strong product pipeline in respiratory is expected to drive
significant growth in the coming years.
-
The company has joined hands with the
NASSCOM Centre of Excellence and the partnership has
led to the discovery of three start- ups.
-
The growth platform of the company is performing well, with innovative
molecules like Brilinta, Forxiga,
Kigduo, Symbicort, Symbicartin and
Komblgyze. The newer launches of
innovative molecules like Tagrisso,
Lynporza and Imitinzi have helped
it make an impact on the lives of
patients. Brilinta is approved for
treatment in acute coronary syndrome and high-risk post-MI patients, and
continues to register rapid
growth even after loss of exclusivity.
-
The company has
been entering into strategic tie-ups
to enrich its business portfolio. It is
on an expansion spree as it is eyeing several deals which
would be beneficial to it. Recently, it collaborated with Bangalore-based
Cellworks to jointly work on designing combination therapies to treat drug-
sensitive and resistant tuberculosis. Farther, the company is engaged in
signing deals
with companies like GlaxoSmithKline and Amylin Pharmaceuticals in order to add
external pieces to their pharmaceutical portions. The company’s partnership
with Sun Pharma
Laboratories has helped boost the reach of a crucial drug to
more patients. This franchise has become the market leader
by value share in oral anti-platenets, as per Iqvia Health.
-
The parent company has undertaken a very ambitious plan to more than double its
new cancer drugs by 2030.
In order to seek the top slot in the world’s most lucrative
category of medicines, AstraZeneca has added seven new
cancer medicines since 2014 after the company’s CEO Pascal
Sariot warded off a hostile takeover from Pfizer Inc. Now,
with blockbuster treatments for malignancies in the lungs,
ovaries and blood, AstraZeneca aspires to be the fastest growing maker of
cancer drugs. The company has thus the opportunity to be the No 1 oncology
player. The Indian outfit will
benefit considerably when the parent company achieves its
aim by 2030, as the menace of cancer is
fast growing in India.
The increasing incidence and diagnosis of NCDs, strategic partnerships from
foreign players with local players, initiatives
to improve access to healthcare and medicines, a positive outlook of the regulatory
environment, associated new drug
launches, implementation of robust digital healthcare initiatives, and expansion
of the healthcare infrastructure are some
of the factors that will drive growth in the
sector in general and in AstraZeneca in
particular. The key contributors to the
growth of the company will be rising income levels, greater health awareness,
increased presence of lifestyle diseases
and improved access to insurance.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2019-20
|
831.80
|
72.00
|
28.80
|
50.0
|
145.80
|
21.70
|
2020-21
|
813.60
|
91.70
|
36.70
|
100.0
|
182.50
|
22.40
|
2021-22
|
805.60
|
59.51
|
23.80
|
500.0
|
204.60
|
12.30
|
COCHIN SHIPYARD
BSE ticker code |
521064 |
NSE ticker code |
TRIDENT |
Major activity |
Other Textile Products |
Chairman |
Rajinder Gupta |
Equity capital |
Rs. 509.60 crore; FV Re. 01 |
52 week high/low |
Rs. 71 / Rs. 13 |
CMP |
Rs. 51.75 |
Market Capitalisation |
Rs. 26371.57 crore |
Recommendation |
Buy at declines |
Expanding shipbuilding footprint
The government of India-owned miniratna PSU, Cochin
Shipyard, is the largest shipbuilding and ship repair facility
in the country. It is the sole shipyard in the country which is
managed by the Ministry of Ports. The company has built
platform supply vessels and double-hulled oil tankers. It is
also a well-known player on the global ship-building front
and has by now exported over 45 ships to various commercial clients overseas. The
company’s
performance on the financial front is
also heart-warming. What is more,
prospects for this mid-cap company
are quite promising going ahead.
Consider:
-
The company has built and
repaired some of the largest ships in
India and also the prestigious indigenous aircraft carrier for the Indian
Navy. Over the years, it has successfully responded to fluctuations in the
ship-building requirements of the
market and has evolved from building bulk carriers to smaller
and more technically sophisticated vessels such as passenger vessels and
offshore support vessels. The company has
worked with several leading technology firms in the industry, including Royce
Marine (Norway), GTT (France) and
Yard Group (Norway). This has added to its credibility in
the international markets. Its key ship-building clients in the
domestic space include the Indian Navy, the Indian Coast
Guard, DRDO, A&N Administration and the JSW group.
The company has a robust order book with pending
orders worth over Rs 10,000 crore and enquiries in addition to benefits it will
get from ‘Make in India’, ‘Atmanirbhar
Bharat’ and indigenous defence orders.
-
The Indian ship-building industry continues to be
driven by defence requirements. The Indian Navy is planning to increase its
fleet from the present 137 to 200 by
2027. This is expected to provide a spurt to the indigenous
ship-building segment. Besides, the Indian Navy’s
indigenisation plan is expected to give a fillip to the growth
of ancillaries and generally improve the ship-building environment in the
country
-
As per the AT Kearney report on the ship repair
industry, though India’s share in global ship repair is less
than 1%, the country’s location is favourable with 7-9% of
global trade passing within 300 nautical miles of the coastline. According to
the report, India has a market potential of
Rs 2,600 crore from repairs to the domestic fleet, of which
only a 15% share is currently captured. The report has further highlighted that
India can
grow its ship repair industry to Rs
9,000 crore in the next 10 years
through infrastructure and process improvement. The report has
highlighted low levels of process
efficiency, lack of infrastructure to
service vessels above 10,000
DWT and a weak ancillary landscape as road blocks for developing the industry.
A key recommendation of the report was to lease
out the repair facilities at major
ports to specialists to augment revenue opportunities.
-
In line with the above recommendations, one of
the major initiatives under the Government of India’s
‘Sagarmala’ project was to lease out the ship repair facilities
available at the major ports to specialists to generate more
revenue and create a positive ship repair industry climate.
Based on this, CSL was offered the first opportunity for ship
repair operations and management of the Indira Dock on
January 18, 2019. CSL has also signed an MoU with Kolkata
Port Trust to take over their Netaji Subhas Dock on lease.
-
According to research analysts of ICICI Securities,
the defence PSU has remained resilient and is seen outperforming the broader
market. It is performing very well with
sales turnover during the last 12 years more than doubling
from Rs 1,462 crore in fiscal 2011 to Rs 3,190 crore in fiscal
2022, operating profit also more than doubling from Rs
308 crore to Rs 637 crore during the same 12-year period,
and the profit at net level shooting up more than two and a
half times – from Rs 228 crore to Rs 587 crore. The compounded sales growth
during the last 10 years works out to
9 per cent and the compounded profit growth around 14
per cent. The new fiscal year ending March 2023 has started
on a highly cheerful note, with revenues in Q1 FY2023
registering a growth of 33.8 per cent yoy to Rs 440.9 crore,
driven by a 31 per cent
yoy growth in the shipbuilding segment and a
47 per cent yoy growth in
the ship repair segment. EBITDA shot up by 50.6 per cent yoy to
Rs 31.5 crore as the EBITDA margin
improved to 7.1 per cent from 6.4 per
cent in Q1 a year ago. Profit at the net
level inched up by 47.2 per cent yoy to
Rs 42.2 crore.
-
The company has been paying dividends regularly and the rate for
the last year was Rs 16.75 per share.
Interestingly, the company has been
maintaining a healthy dividend payout
of 35.1 per cent. The company’s stock is
trading at 1.14 times its book value,
which is quite attractive.
CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2019-20
|
3422.50
|
632.00
|
48.00
|
166.0
|
283.00
|
14.40
|
2020-21
|
2818.90
|
599.20
|
45.50
|
155.0
|
306.60
|
15.50
|
2021-22
|
3190.95
|
565.99
|
43.00
|
168.0
|
334.00
|
13.43
|
TIME TECHNOPLAST
BSE ticker code |
532856 |
NSE ticker code |
TIMETECHNO |
Major activity |
Plastic Products Industrial |
Managing Director |
Sanjay Kulkarni |
Equity capital |
Rs. 22.61 ; FV Rs. 02 |
52 week high/low |
Rs. 126 / Rs. 63 |
CMP |
Rs. 119.95 |
Market Capitalisation |
Rs. 2712.63 crore |
Recommendation |
Buy at declines |
Polymer solutions for varied clients
Time Technoplast is an Indian multinational conglomerate engaged in the manufacture of
technology-driven innovative polymer products, with operations in India, Bahrain,
Egypt, Indonesia, Malaysia, UAE, Taiwan, Thailand, Vietnam,
Saudi Arabia and the US, and more than 34 production
facilities across the globe. These products cater to growing
industry segments like industrial
packaging solutions, life style products, automotive components,
healthcare products, infrastructure/
construction-related products and
material handling solutions.
Promoted by qualified professionals with decades of experience
– who believe in working hard for
the company, its customers, its suppliers, its employees and its shareholders — the
company started as a
small-scale unit with a production
facility in Tarapur (Maharashtra) in 1993, and the very next
year entered into a technological collaboration with the Mauser
group. Then it started expanding its domestic footprint by
setting up a plant at Daman (in the Union Territory of Diu and
Daman) Hosur (Tamil Nadu) and Baddy (Himachal Pradesh).
Having established itself in all parts of the country, Time
Technoplast embarked on a strategic expansion overseas in
the UAE, Bahrain and Thailand in order to serve its customers in the western, southern
and south eastern regions of
Asia. Having covered the Asian region, the company made
inroads in Europe, the US and the Middle East. It also entered into a joint venture
with the Mauser group to acquire
to related businesses in other Asian countries. By now, it
services over 500 institutional clients and its distribution/
dealer network is spread over 345 cities and towns.
The company has been going from strength to strength
on the financial front, with its consolidated sales turnover
during the last 12 years expanding from Rs 1,259 crore in
fiscal 2011 to Rs 3,650 crore in fiscal 2022, with operating
profit inching up from Rs 236 crore to Rs 506 crore during
this period. What is more, prospects ahead are all the more
encouraging.
Consider:
-
Time Technoplast does not have many competitors
globally. Since its inception in 1992, it has set itself apart from
the competition by focusing on R&D,
futuristic product design and superior customer service by setting up 28
manufacturing units and 8 regional
and marketing offices to meet the demand of Indian and global customers. The
company focuses on longterm relationships with customers and
has addressed the varied and expanding requirements of customers
over a long period. By introducing
new products, it has obtained additional business from existing customers and
expanded into new markets.
-
The company has decided to restructure its overseas business in order to
capture growth in Asia, the Middle
East and the US through joint ventures/special purpose vehicles by onboarding
strategic/investor partners by way of
sales/transfer/disposal of part of assets/investments of subsidiaries/ material
subsidiaries/step-down subsidiaries. This
will enable the company to utilize the process of restructuring for repayment
of debt, capex for composite cylinders
(LPG, CNG/hydrogen) and its core business in India to meet
the huge and expanding market demand. This will ultimately
benefit its shareholders substantially.
-
The company has surplus land in Mumbai which it
wants to dispose of. This, along with its overseas proceeds,
will go a long way in wiping out its borrowings which amount
to Rs 906 crore as on March 31, 2022.
-
Time Technoplast is a regular dividend payer, the
rate for last year being 150 per cent. The decline in its debt
will enable the management to step up dividends going ahead.
The company’s financial position is very strong, with reserves
at the end of March 2022 standing at Rs
2,050 crore – almost 90 times its equity
capital of Rs 23 crore. The company has
not made any bonus issue so far, and one
is due now. Discerning investors will do
well to include this scrip in their portfolio.
Shares are available around Rs 117.
The future outlook for the company is
highly positive. Though this is a commodity stock, it is a good buy for long-term
investors.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Series
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2019-20
|
3578.00
|
169.10
|
7.50
|
95.0
|
80.00
|
9.70
|
2020-21
|
3004.90
|
103.40
|
4.60
|
70.0
|
83.90
|
5.60
|
2021-22
|
3649.84
|
187.71
|
8.30
|
100.0
|
91.50
|
9.46
|